| Drug General Information |
| Drug ID |
D00OTT
|
| Former ID |
DNC001810
|
| Drug Name |
ISIS 1570
|
| Drug Type |
Antisense drug
|
| Indication |
Pouchitis [ICD10:K91.8]
|
Approved |
[1]
|
|---|
| Company |
Isis Pharmaceuticals
|
| Target and Pathway |
| Target(s) |
mRNA of Intercellularadhesion molecule-1 |
Target Info |
|
[2]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Cell adhesion molecules (CAMs)
|
|
Natural killer cell mediated cytotoxicity
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
African trypanosomiasis
|
|
Malaria
|
|
Staphylococcus aureus infection
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Rheumatoid arthritis
|
|
Viral myocarditis
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
TSH Signaling Pathway
|
|
IL6 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
ID Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
Pathway Interaction Database
|
Thromboxane A2 receptor signaling
|
|
Glucocorticoid receptor regulatory network
|
|
amb2 Integrin signaling
|
|
Beta2 integrin cell surface interactions
|
|
Reactome
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Integrin cell surface interactions
|
|
Interferon gamma signaling
|
|
WikiPathways
|
Type II interferon signaling (IFNG)
|
|
IL1 and megakaryotyces in obesity
|
|
Human Complement System
|
|
Spinal Cord Injury
|
|
Interleukin-11 Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin cell surface interactions
|
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 2 | US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion. |
|---|
